Prognostic factor analysis for PFS at diagnosis
| . | Univariate (log rank) . | Multivariate (Cox regression) . | |
|---|---|---|---|
| P . | HR (95% CI) . | P . | |
| Pretreatment Bcl-2/ IgH level | .000 | 3.433 (1.659-7.101) | .001 |
| >1 | |||
| <1 | |||
| Ann Arbor stage | .062 | 1.415 (0.530-3.778) | .488 |
| IV | |||
| ≤III | |||
| Spleen involvement | .062 | 1.183 (0.571-2.449) | .652 |
| Yes | |||
| No | |||
| Age | .068 | 0.679 (0.334-1.380) | .284 |
| >60 y | |||
| <60 y | |||
| FLIPI (score) and risk groups | .088 | 1.534 (0.405-5.803) | .529 |
| (≥2) intermediate and high risk | |||
| (0-1) low risk | |||
| BM involvement | .143 | n.a. | |
| Yes | |||
| No | |||
| β2-microglobulin serum level | .171 | n.a. | |
| >3 mg/L | |||
| <3 mg/L | |||
| . | Univariate (log rank) . | Multivariate (Cox regression) . | |
|---|---|---|---|
| P . | HR (95% CI) . | P . | |
| Pretreatment Bcl-2/ IgH level | .000 | 3.433 (1.659-7.101) | .001 |
| >1 | |||
| <1 | |||
| Ann Arbor stage | .062 | 1.415 (0.530-3.778) | .488 |
| IV | |||
| ≤III | |||
| Spleen involvement | .062 | 1.183 (0.571-2.449) | .652 |
| Yes | |||
| No | |||
| Age | .068 | 0.679 (0.334-1.380) | .284 |
| >60 y | |||
| <60 y | |||
| FLIPI (score) and risk groups | .088 | 1.534 (0.405-5.803) | .529 |
| (≥2) intermediate and high risk | |||
| (0-1) low risk | |||
| BM involvement | .143 | n.a. | |
| Yes | |||
| No | |||
| β2-microglobulin serum level | .171 | n.a. | |
| >3 mg/L | |||
| <3 mg/L | |||
Data on 107 patients were available for univariate and multivariate analysis; n.a. indicates not close to significance in univariate analysis (P > .1) and therefore not included in multivariate analysis.